CA2395324A1 - Expression potentiator for protein synthesis regulatory gene - Google Patents
Expression potentiator for protein synthesis regulatory gene Download PDFInfo
- Publication number
- CA2395324A1 CA2395324A1 CA002395324A CA2395324A CA2395324A1 CA 2395324 A1 CA2395324 A1 CA 2395324A1 CA 002395324 A CA002395324 A CA 002395324A CA 2395324 A CA2395324 A CA 2395324A CA 2395324 A1 CA2395324 A1 CA 2395324A1
- Authority
- CA
- Canada
- Prior art keywords
- ifn
- alpha
- subtypes
- expression
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- AIDS & HIV (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000-328539 | 2000-10-27 | ||
| JP2000328539 | 2000-10-27 | ||
| JP2001116710A JP2002201141A (ja) | 2000-10-27 | 2001-04-16 | 蛋白質合成抑制遺伝子の発現増強剤 |
| JP2001-116710 | 2001-04-16 | ||
| PCT/JP2001/008390 WO2002036153A1 (en) | 2000-10-27 | 2001-09-26 | Expression potentiator for protein synthesis regulatory gene |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2395324A1 true CA2395324A1 (en) | 2002-05-10 |
Family
ID=26602905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002395324A Abandoned CA2395324A1 (en) | 2000-10-27 | 2001-09-26 | Expression potentiator for protein synthesis regulatory gene |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US6773701B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1329223A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2002201141A (cg-RX-API-DMAC7.html) |
| KR (1) | KR100830268B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2395324A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TWI283582B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2002036153A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9453251B2 (en) | 2002-10-08 | 2016-09-27 | Pfenex Inc. | Expression of mammalian proteins in Pseudomonas fluorescens |
| JP4629964B2 (ja) * | 2003-09-12 | 2011-02-09 | 株式会社林原生物化学研究所 | ウシの消化器疾患治療剤 |
| CN101031655A (zh) | 2004-07-26 | 2007-09-05 | 陶氏环球技术公司 | 通过株工程改进蛋白表达的方法 |
| EP1867340A4 (en) | 2005-03-10 | 2009-12-23 | Hayashibara Biochem Lab | THERAPEUTIC AGENT FOR TREATING DISEASES IN THE BOVINE DIGESTIVE SYSTEM |
| JPWO2007037098A1 (ja) * | 2005-09-27 | 2009-04-02 | 株式会社林原生物化学研究所 | 繁殖障害改善剤 |
| US9580719B2 (en) | 2007-04-27 | 2017-02-28 | Pfenex, Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
| US9394571B2 (en) | 2007-04-27 | 2016-07-19 | Pfenex Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
| CN104056254A (zh) * | 2013-03-18 | 2014-09-24 | 赛德医药科技股份有限公司 | 用以降低肝炎病患复发率的组合物 |
| US10077420B2 (en) | 2014-12-02 | 2018-09-18 | Histogenics Corporation | Cell and tissue culture container |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5142199B2 (cg-RX-API-DMAC7.html) | 1972-09-04 | 1976-11-13 | ||
| GB2016015B (en) | 1978-01-22 | 1982-05-06 | Hayashibara Co | Method of preparing interferon and preparations containing interferon |
| JPS5639022A (en) | 1979-09-05 | 1981-04-14 | Hayashibara Biochem Lab Inc | Preparation of vaccine |
| JPS5654158A (en) | 1979-10-09 | 1981-05-14 | Hitachi Ltd | Control system for call waiting |
| JP2838800B2 (ja) | 1989-09-02 | 1998-12-16 | 株式会社林原生物化学研究所 | 減感作剤 |
| US5503828A (en) * | 1992-02-10 | 1996-04-02 | Interferon Sciences, Inc. | Alpha interferon composition and method for its production from human peripheral blood leukocytes |
| JP3232488B2 (ja) | 1992-08-20 | 2001-11-26 | 株式会社林原生物化学研究所 | プルラン高含有物とその製造方法並びに用途 |
| US5780021A (en) * | 1993-03-05 | 1998-07-14 | Georgetown University | Method for treating type 1 diabetes using α-interferon and/or β-i |
| JPH07163368A (ja) | 1993-12-15 | 1995-06-27 | Hayashibara Biochem Lab Inc | 組換えdnaとその組換えdnaを含む形質転換体 |
| EP0785276A4 (en) | 1994-09-29 | 2002-01-09 | Ajinomoto Kk | MODIFICATION OF A PEPTIDE AND A PROTEIN |
| JP3467515B2 (ja) * | 1994-11-01 | 2003-11-17 | 財団法人ルイ・パストゥール医学研究センター | インターフェロン活性の測定法 |
| MY125300A (en) * | 1999-02-26 | 2006-07-31 | Inst Of Molecular And Cell Biology | Synergistic combination for treatment of viral-mediated diseases |
-
2001
- 2001-04-16 JP JP2001116710A patent/JP2002201141A/ja active Pending
- 2001-09-26 US US09/962,625 patent/US6773701B2/en not_active Expired - Fee Related
- 2001-09-26 CA CA002395324A patent/CA2395324A1/en not_active Abandoned
- 2001-09-26 KR KR1020027008401A patent/KR100830268B1/ko not_active Expired - Fee Related
- 2001-09-26 EP EP01972507A patent/EP1329223A4/en not_active Ceased
- 2001-09-26 WO PCT/JP2001/008390 patent/WO2002036153A1/ja not_active Ceased
- 2001-10-15 TW TW090125438A patent/TWI283582B/zh not_active IP Right Cessation
-
2004
- 2004-02-13 US US10/777,081 patent/US7189389B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1329223A1 (en) | 2003-07-23 |
| KR100830268B1 (ko) | 2008-05-16 |
| US6773701B2 (en) | 2004-08-10 |
| US20040197307A1 (en) | 2004-10-07 |
| US7189389B2 (en) | 2007-03-13 |
| KR20020065620A (ko) | 2002-08-13 |
| EP1329223A4 (en) | 2005-04-20 |
| JP2002201141A (ja) | 2002-07-16 |
| US20030039629A1 (en) | 2003-02-27 |
| TWI283582B (en) | 2007-07-11 |
| WO2002036153A1 (en) | 2002-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100223255B1 (ko) | 개량된 알파 인터페론 조성물 및 인간 말초혈 백혈구로 부터의 제조 방법 | |
| Grace et al. | Structural and biologic characterization of pegylated recombinant IFN-α 2b | |
| US5981709A (en) | α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same | |
| ES2436761T3 (es) | Mutantes de interferón alfa 2 (IFN alfa 2) recombinante | |
| Lefevre et al. | A novel and atypical type one interferon gene expressed by trophoblast during early pregnancy. | |
| KR100496460B1 (ko) | 폴리펩티드 | |
| Schultz et al. | Recombinant chicken interferon from Escherichia coli and transfected COS cells is biologically active | |
| JPWO1990010651A1 (ja) | ヒト由来の糖蛋白質及び該糖蛋白質からなる生理活性因子とそれを活性成分とする製剤 | |
| US6773701B2 (en) | Expression enhancer for protein synthesis inhibitory genes | |
| CN103483443A (zh) | 重组人干扰素样蛋白 | |
| Masci et al. | New and modified interferon alfas: preclinical and clinical data | |
| EP1326628B1 (en) | Chemokine mutants in the treatment of multiple sclerosis | |
| JP3226918B2 (ja) | 腫瘍壊死因子とインターロイキン−4の相乗作用 | |
| JPH0550273B2 (cg-RX-API-DMAC7.html) | ||
| US6207641B1 (en) | Pharmaceutical composition containing IFN-γ inducing polypeptide or factor for treating and/or preventing IFN-γ susceptive diseases | |
| CZ20024094A3 (cs) | Farmaceutický přípravek pro léčení sclerosis multiplex obsahující nový interferon | |
| Franco et al. | Biological activities of a human amniotic membrane interferon | |
| KR100891918B1 (ko) | Ifnar2 돌연변이, 및 그 제조방법 및 용도 | |
| RU2003334C1 (ru) | Способ лечени больных с опухол ми | |
| US6774220B1 (en) | Compounds having lectinic properties and their biological applications | |
| Hayes | Differences between human α (leukocyte) and β (fibroblast) interferons | |
| Cheng et al. | Accumulation of Guanylate Binding Proteins in Patients Treated with Interfeons | |
| Horisberger et al. | Induction of Mx-related protein in cat peripheral blood mononuclear cells after administration of recombinant human interferon hybrid | |
| Finter | The classification and biological functions of the interferons: A review | |
| KR20080037656A (ko) | 저독성의 장시간 순환하는 사람 인터페론-알파 유사체 및인터페론 타우의 키메라 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |